| Status | In progress |
| Process | HST |
| ID number | 1473 |
Provisional Schedule
| Committee meeting: 1 | 26 March 2020 |
| Expected publication | 08 September 2020 |
Project Team
| Project lead | Jo Ekeledo |
Email enquiries
- If you have any queries please email HST@nice.org.uk
Consultees
| Companies sponsors | AveXis |
| Others | Department of Health and Social Care |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Muscular Dystrophy UK |
| Spinal Muscular Atrophy UK (SMA UK) | |
| The Annabelle Rose Foundation for Spinal Muscular Atrophy | |
| TreatSMA | |
| Professional groups | Association of British Neurologists |
| British Society for Children's Orthopaedic Surgery | |
| Royal College of Pathologists | |
| Royal College of Physicians |
Commentators
| Comparator companies | Biogen |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | None |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 17 October 2019 | The company which markets this technology have advised NICE of an extension to their regulatory timings. Therefore the first committee discussion scheduled to take place on Thursday 28 November 2019 has been rescheduled and will now take place on Thursday 26 March 2020 at NICE Manchester |
| 06 June 2019 | Invitation to participate |
| 03 June 2019 | In progress, To evaluate the benefits and costs of onasemnogene abeparvovec within its marketing authorisation for treating spinal muscular atrophy type 1 for national commissioning by NHS England |
| 06 November 2018 (10:00) | Scoping workshop (Manchester) |
| 19 September 2018 - 17 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on how we develop guidance, please see our page about NICE highly specialised technologies guidance